Lenka Hanousková1, Jakub Řezáč2, Štěpán Veselý2, Richard Průša1, Karel Kotaška1. 1. Charles University, Second Faculty of Medicine, University Hospital Motol, Department of Medical Chemistry and Clinical Biochemistry, Prague, Czech Republic. 2. Charles University, Second Faculty of Medicine, University Hospital Motol, Department of Urology, Prague, Czech Republic.
Abstract
BACKGROUND: It has been shown that decreased expression and activity of extracellular matrix protein mindin correlate with various types of cancers including breast, colon and lung cancers. The aim of the presented study was to investigate the serum mindin levels in prostate cancer. METHODS: Mindin concentrations in serum were measured in 56 patients with prostate cancer (mean age 68 years) and in control group of 29 healthy men (mean age 64 years) using commercially available enzymatic immunoassay (Cusabio, WuHan, China). The patients were divided with respect to the severity of the disease into two groups according to the EAU guidelines (stage 1, 2 - less severe tumours, stage 3, 4 - severe tumours). RESULTS: Serum mindin concentrations were significantly elevated in the group of healthy individuals unlike in the patients with prostate cancer (2.12 ng/mL vs 0.78 ng/mL, with P=0.0007, AUC=0.705). Patients with less severe tumours (stage 1, 2) and severe tumours (stage 3, 4) had significantly decreased levels of S-mindin as well (P=0.0037), although the difference in serum mindin concentrations between the patients with less severe and severe tumours was not significant. CONCLUSIONS: Concentrations of mindin were decreased in patients with prostate cancer and reduced in patients with less severe prostate cancer as well. Mindin appears to be a promising diagnostic marker useful in the diagnosis of prostate cancer. 2020 Lenka Hanousková, Jakub Řezáč, Štěpán Veselý, Richard Průša, Karel Kotaška, published by CEON/CEES.
BACKGROUND: It has been shown that decreased expression and activity of extracellular matrix protein mindin correlate with various types of cancers including breast, colon and lung cancers. The aim of the presented study was to investigate the serum mindin levels in prostate cancer. METHODS: Mindin concentrations in serum were measured in 56 patients with prostate cancer (mean age 68 years) and in control group of 29 healthy men (mean age 64 years) using commercially available enzymatic immunoassay (Cusabio, WuHan, China). The patients were divided with respect to the severity of the disease into two groups according to the EAU guidelines (stage 1, 2 - less severe tumours, stage 3, 4 - severe tumours). RESULTS: Serum mindin concentrations were significantly elevated in the group of healthy individuals unlike in the patients with prostate cancer (2.12 ng/mL vs 0.78 ng/mL, with P=0.0007, AUC=0.705). Patients with less severe tumours (stage 1, 2) and severe tumours (stage 3, 4) had significantly decreased levels of S-mindin as well (P=0.0037), although the difference in serum mindin concentrations between the patients with less severe and severe tumours was not significant. CONCLUSIONS: Concentrations of mindin were decreased in patients with prostate cancer and reduced in patients with less severe prostate cancer as well. Mindin appears to be a promising diagnostic marker useful in the diagnosis of prostate cancer. 2020 Lenka Hanousková, Jakub Řezáč, Štěpán Veselý, Richard Průša, Karel Kotaška, published by CEON/CEES.
Authors: Axel Heidenreich; Gunnar Aus; Michel Bolla; Steven Joniau; Vsevolod B Matveev; Hans Peter Schmid; Filliberto Zattoni Journal: Eur Urol Date: 2007-09-19 Impact factor: 20.096
Authors: Sigve Nakken; Wolfgang Lilleby; Marta D Switlyk; Karen E Knudsen; Oscar Lilleby; Sen Zhao; Fatemeh Kaveh; Per O Ekstrøm; Alfonso Urbanucci; Eivind Hovig Journal: J Pers Med Date: 2021-04-22
Authors: Luis Álvarez-Carrión; Irene Gutiérrez-Rojas; María Rosario Rodríguez-Ramos; Juan A Ardura; Verónica Alonso Journal: Cancers (Basel) Date: 2021-01-24 Impact factor: 6.639